Natto: Release of NattoPharma 's results for Q3 2015 Wednesday 25. November 2015 at 08:00 hours

The same day, the company will hold a presentation of the quarterly results at the conference center of KS - Agenda, Haakon VII's gate 9, Oslo 25. November 2015 at 08.30 hours.

The presentation will be held by CEO Hogne Vik. Breakfast will be served.

About MenaQ7®

MenaQ7® provides natural vitamin K2 as a manufactured fermentation extract. This
process generates a highly pure and bio-available form of vitamin K2,
menaquinone-7 (MK-7). MenaQ7 is the purest vitamin K2 on the market. MenaQ7 is
the only vitamin K2 with proven positive clinical health effects on bones and
the cardiovascular system. MenaQ7 vitamin K2 is the only vitamin K2 supported by
several granted patents on cardiovascular health worldwide.

About NattoPharma

As a biotechnology and nutraceutical company, NattoPharma is the worldwide
pioneer and innovator for developing, documenting and provide Vitamin K2
menaquinone-7. Its brand MenaQ7® is supported by a global IPR portfolio and
research substantiating clear positive clinical efficacy for bone and
cardiovascular health. NattoPharma has since 2007 been in a research and
development collaboration with VitaK, University in Maastricht, The Netherlands,
working to substantiate the health benefits of natural vitamin K2.

For more information, please contact:

Hogne Vik

CEO, NattoPharma

Mobil: +47 97 53 53 26

Tags:

About Us

NattoPharma, the world leader in Vitamin K2 Research and Development, has invested millions of dollars in in-vitro, in-vivo, and clinical studies to document the effects of MenaQ7® Vitamin K2 as MK-7. This commitment has created the only patented and clinically validated K2 on the market. After establishing the first commercial Vitamin K2 with its flagship brand, MenaQ7®, NattoPharma has consistently answered and met market needs through the development of new production technologies:• In 2012, the company introduced MenaQ7® Crystals, which represented an important breakthrough in the new generation of Vitamin K2 products, producing the purest natural MK-7 available.• In 2014, NattoPharma introduced the only all-trans nature-identical synthesized Vitamin K2, MenaQ7® PURE. Not only did the company succeed in changing the market with MenaQ7® PURE – offering a high-quality, competitively priced ingredient – but its efforts were rewarded with the NutrAward for Best Functional Ingredient at Natural Products West/engredea 2015. Vitamin K2 is essential for the body to utilize calcium to build healthy, strong bones and to inhibit calcium deposits in the arteries. Published clinical studies have demonstrated the high bioavailability and proof of efficacy for Nattopharma’s all-trans MK-7 products in healthy and diseased populations, for bone and cardiovascular health. NattoPharma continues to build its competitive advantage through focuson IPR and has patents both granted and pending related to relevant healthbenefits and market segments, creating extra value for its customers. And NattoPharma staff consists of professionals people with longstanding experience in medical and biochemical research as well as pharmaceutical and food supplement development. By understanding and controlling the chemistry, NattoPharma provides the market all-trans MK-7 products, while our sales and marketing team has extensive knowledge of international market demands with which it supports our partners.

Subscribe